135050-95-2

Upstream product

• 18282-51-4 4-iodo-benzyl alcohol 
• 6999-03-7 1-bromo-4-(trimethylsilyl)benzene 
• 1711-02-0 4-iodobenzoic acid chloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 143722-25-2 2-(2'-Triphenylmethyl-2'H-tetrazol-5'-yl)-phenylboronic acid 
• 106-37-6 1.4-dibromobenzene 
• 619-58-9 4-iodobenzoic acid 
• 157756-27-9 5-<4'-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl><1,1'-biphenyl>-2-yl>-2-(triphenylmethyl)-1H-tetrazole 
• 138804-35-0 2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1-biphenyl-4-carboxaldehyde 
• 160514-13-6 2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-methanol 
• 76-83-5 trityl chloride 
• 15290-29-6 4-(trimethylsilyl)benzoic acid 

Downstream Products

• 143722-28-5 5-(4'-Methanesulfonyloxymethyl-1,1'-biphenyl-2-yl)-2-triphenylmethyl-2H-tetrazole 
• 150438-02-1 CI 996 
• 1027968-99-5 2-Propyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5-[2-(2,2,2-trifluoro-acetyl)-pyrrol-1-yl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 1026262-77-0 2-Propyl-5-[2-(2,2,2-trifluoro-acetyl)-pyrrol-1-yl]-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid ethyl ester 
• 138804-35-0 2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1-biphenyl-4-carboxaldehyde 
• 172875-59-1 ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl-1H-imidazole-5-carboxylate 

Relevant academic research and scientific papers

Preparation method of olmesartan medoxomil

The invention discloses a preparation method of olmesartan medoxomil. The preparation method comprises the following steps of using 4-bromobenzaldehyde as a starting raw material, performing Suzuki coupling reaction with 2-(2'-triphenylmethyl tetrazole-5-yl)borophenylic acid (III), and reducing by NaBH4 (sodium borohydride), so as to obtain an olmesartan medoxomil intermediate of N-triphenylmethyl-5-(4'-hydroxymethyl biphenyl-2-yl)tetrazole (IV); directly reacting the intermediate (IV) and 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester, so as to obtain a compound VI; performing hydrolysis, esterification and deprotection, so as to obtain the olmesartan medoxomil. Compared with the prior art, the preparation method has the advantages that the obtaining of raw materials is easy, the amount of byproducts is fewer, the reaction line is shortened, the reaction condition is mild, the operation is simple, the total yield of product is improved, and the preparation method is suitable for industrialized production.

Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use

The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

Model reactions targeted at the synthesis of carbon-14 labeled CI-996, a potent antagonist of angiotensin II receptor (1)

A reaction sequence suitable for the preparation of an analog of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-4-[2-(tr ifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid, with 14C at the methylene bridge was developed. The would-be labeled fragment (12) was derived from 4-iodobenzenemethanol (6) which itself was constructed from 1,4-dibromobenzene by the application of silicon chemistry. Pd(o) catalyzed coupling of TBDMS protected 6 and a tetrazole borate 10 gave the compound 12 which upon further transformation to the mesylate 13, N-alkylated an imidazole to furnish target compound.

PROCESS FOR PREPARING BIPHENYLTETRAZOLE COMPOUNDS

Method for the preparing biphenyltetrazole compounds which are angiotensin II receptor antagonists or which are useful intermediates to prepare angiotensin II receptor antagonists. An illustrative biphenyl tetrazole compound is 2-n-butyl-4-chloro-1-[(2'-(tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imi dazole-5-methanol, potassium salt.